Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Research Technology Selects Maybridge Fragments for Lead Discovery Programmes

Published: Friday, May 22, 2009
Last Updated: Friday, May 22, 2009
Bookmark and Share
CRT purchases 2,000 Maybridge Fragments as the foundation of its new fragment screening library.

Thermo Fisher Scientific has announced that Cancer Research Technology (CRT) has purchased 2,000 Maybridge Fragments as the foundation of its new fragment screening library. Wholly owned by the internationally renowned charity, Cancer Research UK, CRT is a specialist oncology-focused development and commercialization company.

Selected for its high quality, the Maybridge Fragment Collection will be used in CRT’s established discovery laboratories in London and Cambridge, for fragment-based screening, a key technology to accelerate the identification of drug leads against novel cancer targets.

“Having reviewed several vendor catalogues with a focus on fragment collections for a discrete selection of heterocyclic small molecules with suitable properties, we ultimately chose the Maybridge Fragment Collection due to its superior overall fit to our requirements,” explained Dr. Martin Swarbrick, Group Leader, Medicinal Chemistry, at CRT. “A good fit to ‘Rule-of-Three’ principles for physicochemical properties was essential, as well as lead-likeness and ‘drug-ability’.”

Other key features of the Maybridge Fragment collection that influenced the CRT selection process include its high compound purity and chemical diversity, which is supported by related synthons elsewhere in the Maybridge catalogue. The availability of related building blocks featuring the same fragments from Maybridge stock facilitates the construction of a library around chosen core fragments for hit-to-lead work and further optimization.

“Other factors in our decision to purchase the Maybridge Fragment selection were their immediate and reliable availability for prompt follow up work, as well as the favorable pricing,” added Swarbrick.

“We are very proud to have been selected by such an eminent cancer technology transfer company due to the quality, diversity and flexibility of our Fragment Collection,” said Dr.Mick Durrant, Director of Business Development for Maybridge products at Thermo Fisher Scientific. “We pride ourselves on our choice of off-the-shelf collections and the ability to pick from our carefully selected fragment lists. This enables our customers to create their own bespoke libraries, giving them both convenience and complete control over their fragment screening programmes to ultimately accelerate lead generation.”

The Maybridge Fragment collection is a convenient source of pre-selected, high quality building blocks which is a distillation of Maybridge’s combined expertise in heterocyclic compound design. Over 30,000 compounds have been assembled to form a pool from which researchers can build their own customized fragment libraries. This collection has been selected for purity, low molecular weight and absence of inappropriate functionality. All compounds are easily re-supplied and available custom weighed in mgs or µmols.

Many of the Maybridge Fragments are fully “Rule-of-Three” compliant, which means that the physicochemical properties of these fragments are optimal; therefore increasing the probability of future “hit” successes. Consequently, Maybridge Fragments provide an ideal starting point for a lead optimization drug discovery programme and the ultimate evolution of a new molecule in the drug discovery process.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo, Children’s Hospital Los Angeles Partner
Children’s Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA’s first NGS panel designed to target biomarkers associated with childhood cancers.
Friday, February 19, 2016
Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
Companies pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs.
Monday, June 02, 2014
Thermo Fisher Scientific Announces 4th Annual Cellome Award Winner
Vishal Deshmukh, Scripps Institute to accept award for excellence in the application of high content technology in Multiple Sclerosis research.
Wednesday, February 26, 2014
Thermo Reports 6% Q4 Revenue Growth
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2013.
Friday, January 31, 2014
One Lambda Receives CE Mark Approval for C1qScreen
Assay cited in New England Journal of Medicine for use in determining impact on kidney graft survival.
Tuesday, November 19, 2013
Thermo Scientific Selected to Supply Maybridge Fragment Library for Key Research
Recommended for use by renowned fragment library design expert.
Tuesday, February 05, 2013
Record Revenues for Thermo Fisher Scientific
Revenue for the quarter grew 6% to $3.26 billion in 2012, versus $3.09 billion in 2011.
Thursday, January 31, 2013
Thermo Scientific Enters into a Long-Term Agreement with Fujirebio
Combination of Thermo Scientific B•R•A•H•M•S PCT assay and Lumipulse platforms to test patients suspected of having sepsis.
Thursday, November 22, 2012
Thermo Fisher Scientific Announces Application Deadlines for Life Sciences Scholarships
Thermo Scientific Pierce Scholarship Winter/Spring semester applications due December 14, 2012.
Wednesday, November 14, 2012
Thermo Fisher Scientific Introduces Guide to Good Washing Practice
The online guide is designed to provide detailed guidance on obtaining secure and reliable performance with every use of the Thermo Scientific Wellwash microplate washers.
Thursday, October 21, 2010
Thermo Fisher Scientific Launches Maybridge Ro3 Diversity Fragment Library
Diverse set of 1,500 molecules engineered for high-quality fragment screening-based programmes.
Tuesday, July 06, 2010
Thermo Fisher Scientific Names Recipients of RNAi Discovery Grants
More than $400,000 in RNAi screening tools awarded to advance biomedical research and drug discovery.
Friday, November 06, 2009
Thermo Fisher Scientific Signs Agreement to Acquire B.R.A.H.M.S. AG
Company acquires provider of specialty in-vitro diagnostic tests for $470 million USD.
Monday, September 07, 2009
Thermo Fisher Scientific to Showcase Innovative Mass Spectrometry Solutions at IMSC 2009
Company will showcase a variety of mass spectrometry software and hardware solutions to deliver improved analytical performance.
Monday, September 07, 2009
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Using Gene-editing Technology for Faster, Cheaper Antiviral Drug Development
UCLA scientists are working to develop special screening libraries based on a gene-editing technology called CRISPR.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!